Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
Giuliano
Marina
M
Galluzzo
Clementina M
CM
Germinario
Elena A P
EA
Amici
Roberta
R
Bassani
Luciana
L
Dehò
Lorenzo
L
Vyankandondera
Joseph
J
Mmiro
Francis
F
Okong
Pius
P
Vella
Stefano
S
D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D016333:HIV Protease / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use*; D009154:Mutation; D019829:Nevirapine / Q000494:pharmacology / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D012194:RNA-Directed DNA Polymerase / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012432:Rwanda; D012641:Selection, Genetic; D013045:Species Specificity; D016896:Treatment Outcome; D014454:Uganda
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D012194:RNA-Directed DNA Polymerase; D016333:HIV Protease